US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lexeo Therapeutics

4.02

-0.1000-2.43%

Post-market: 3.81-0.2100-5.22%16:21 EDT

Volume:281.77K

Turnover:1.14M

Market Cap:220.51M

PE:-1.22

High:4.18

Open:4.13

Low:3.96

Close:4.12

Loading ...

Overview Company News Filings

Lexeo Therapeutics Q1 EPS $(0.99) Misses $(0.78) Estimate

Press Release: Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

Lexeo Therapeutics Inc expected to post a loss of 78 cents a share - Earnings Preview

H.C. Wainwright Keeps Their Buy Rating on Lexeo Therapeutics, Inc. (LXEO)

Undervalued Penny Stocks To Consider In May 2025

Simply Wall St.

Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Chardan Research Adjusts Lexeo Therapeutics Price Target to $22 From $25, Maintains Buy Rating

MT Newswires Live

Lexeo Therapeutics Price Target Maintained With a $23.00/Share by HC Wainwright & Co.

Lexeo Therapeutics Is Maintained at Buy by Chardan Capital

Lexeo Therapeutics Inc : Chardan Capital Markets Cuts Target Price to $22 From $25

THOMSON REUTERS

Lexeo Therapeutics Says Potential FA Cardiomyopathy Therapy Improves Cardiac Biomarkers

MT Newswires Live

BRIEF-Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data For Lx2006 In Friedreich Ataxia Cardiomyopathy Supporting Advancement To Registrational Study

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for Lx2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

THOMSON REUTERS

Lexeo Therapeutics Inc: Lx2006 Generally Well Tolerated With No Signs of Complement Activation or Other Immunogenicity to Date

THOMSON REUTERS

Lexeo Therapeutics : Clinically Meaningful Improvements in Majority of Participants Across Cardiac Biomarkers & Functional Measures

THOMSON REUTERS

Lexeo Therapeutics : Participants With Abnormal Left Ventricular Mass Index at Baseline Achieved 25% Mean Reduction in Lvmi by 12 Months or Sooner

THOMSON REUTERS

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

Lexeo Therapeutics Price Target Maintained With a $23.00/Share by HC Wainwright & Co.

Lexeo Therapeutics price target lowered to $18 from $19 at Leerink

Lexeo Therapeutics price target lowered to $20 from $24 at RBC Capital

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/LXEO/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LXEO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LXEO\",,,,,undefined,":{"symbol":"LXEO","market":"US","secType":"STK","nameCN":"Lexeo Therapeutics","latestPrice":4.02,"timestamp":1751313600000,"preClose":4.12,"halted":0,"volume":281768,"hourTrading":{"tag":"盘后","latestPrice":3.81,"preClose":4.02,"latestTime":"16:21 EDT","volume":7277,"amount":29232.538578000003,"timestamp":1751314909441},"delay":0,"floatShares":40088912,"shares":54854400,"eps":-3.305219,"marketStatus":"Post-Mkt","change":-0.1,"latestTime":"06-30 16:47:16 EDT","open":4.13,"high":4.1794,"low":3.9599,"amount":1143343.113287,"amplitude":0.053277,"askPrice":4.38,"askSize":4,"bidPrice":3.81,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-3.305219,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1751328000000},"marketStatusCode":4,"adr":0,"listingDate":1698984000000,"exchange":"NASDAQ","adjPreClose":4.12,"preHourTrading":{"tag":"盘前","latestPrice":4.3432,"preClose":4.12,"latestTime":"09:29 EDT","volume":725,"amount":3133.1921175,"timestamp":1751290171070},"postHourTrading":{"tag":"盘后","latestPrice":3.81,"preClose":4.02,"latestTime":"16:21 EDT","volume":7277,"amount":29232.538578000003,"timestamp":1751314909441},"volumeRatio":0.448194,"impliedVol":1.4008,"impliedVolPercentile":0.5255},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LXEO\",,,,,undefined,":{"symbol":"LXEO","floatShares":40088912,"roa":"-42.89%","roe":"-80.65%","lyrEps":-3.093449,"volumeRatio":0.448194,"shares":54854400,"dividePrice":0,"high":4.1794,"amplitude":0.053277,"preClose":4.12,"low":3.9599,"week52Low":1.45,"pbRate":"2.50","week52High":19.5,"institutionHeld":0,"latestPrice":4.02,"committee":-0.6,"eps":-3.305219,"divideRate":0,"volume":281768,"delay":0,"ttmEps":-3.305219,"open":4.13,"prevYearClose":6.58,"prevWeekClose":4.12,"prevMonthClose":2.72,"prevQuarterClose":3.47,"fiveDayClose":3.96,"twentyDayClose":2.72,"sixtyDayClose":2.945},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LXEO\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2534225072","title":"Lexeo Therapeutics Q1 EPS $(0.99) Misses $(0.78) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2534225072","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534225072?lang=en_us&edition=fundamental","pubTime":"2025-05-12 19:13","pubTimestamp":1747048405,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $(0.78) by 26.92 percent. This is a 28.57 percent decrease over losses of $(0.77) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45344017/lexeo-therapeutics-q1-eps-0-99-misses-0-78-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO"],"gpt_icon":0},{"id":"2534223741","title":"Press Release: Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2534223741","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534223741?lang=en_us&edition=fundamental","pubTime":"2025-05-12 19:00","pubTimestamp":1747047600,"startTime":"0","endTime":"0","summary":"Announced positive interim data for LX2006 from Phase 1/2 studies in Friederich ataxia  cardiomyopathy; frataxin expression and LVMI improvement exceeded co-primary target thresholds for planned registrational study. LX2006 registrational study expected to begin by early 2026; commencing enrollment in prospective natural history study, CLARITY-FA, in Q2 2025 to serve as concurrent external control. Phase 1/2 clinical trial of LX2020  currently enrolling patients in Cohort 3; interim clinical data update on track for second half of 2025. Redeployed $20 million to focus on clinical-stage programs; cash, cash equivalents and investments of $106.9 million expected to provide operational runway into 2027. \"Based on the highly encouraging clinical data shared to date, we believe LX2006 could be transformational and establish a new standard of care in FA cardiomyopathy,\" said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. \"We look forward to beginning enrollment in the CLAR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4139","BK4130","LXEO","FA","BK4539"],"gpt_icon":0},{"id":"2533980440","title":"Lexeo Therapeutics Inc  expected to post a loss of 78 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2533980440","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533980440?lang=en_us&edition=fundamental","pubTime":"2025-05-07 20:53","pubTimestamp":1746622387,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics Inc  expected to post a loss of78cents a share - Earnings Preview Lexeo Therapeutics Inc LXEO.OQ LXEO.O is expected to show no change in quarterly revenue when it reports  results o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nL8N3RF1PJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO"],"gpt_icon":0},{"id":"2533520948","title":"H.C. Wainwright Keeps Their Buy Rating on Lexeo Therapeutics, Inc. (LXEO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2533520948","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533520948?lang=en_us&edition=fundamental","pubTime":"2025-05-06 15:55","pubTimestamp":1746518121,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Mitchell Kapoor maintained a Buy rating on Lexeo Therapeutics, Inc. (LXEO – Research Report) yesterday and set a price targ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-lexeo-therapeutics-inc-lxeo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-lexeo-therapeutics-inc-lxeo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXEO"],"gpt_icon":0},{"id":"2532843473","title":"Undervalued Penny Stocks To Consider In May 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2532843473","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532843473?lang=en_us&edition=fundamental","pubTime":"2025-05-02 20:04","pubTimestamp":1746187487,"startTime":"0","endTime":"0","summary":"The market has climbed 1.8% in the last 7 days and is up 9.5% over the last 12 months, with earnings expected to grow by 14% per annum over the next few years. In such a climate, identifying stocks with strong fundamentals can be key to uncovering hidden value. Though often seen as a relic of past trading days, penny stocks—typically representing smaller or newer companies—still offer potential for significant returns when backed by solid financials.Lexeo Therapeutics, with a market cap of US$130.46 million, remains pre-revenue but has shown promising clinical progress. Recent positive interim data from its LX2006 trials for Friedreich ataxia cardiomyopathy supports advancement to a registrational study by early 2026. Despite being debt-free and having short-term assets exceeding liabilities, the company's cash runway is limited to just over a year if current cash flow trends persist. While losses have increased over the past five years, Lexeo's management is relatively new and earning","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/undervalued-penny-stocks-consider-may-120447113.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4509","LXEO","BK4209","BK4505","IDTA","BK4179","BABB","BK4021","BK4526","SB","PERF","TUYA","BK4023","OIS","BK4563"],"gpt_icon":0},{"id":"2532077041","title":"Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2532077041","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532077041?lang=en_us&edition=fundamental","pubTime":"2025-05-01 21:16","pubTimestamp":1746105360,"startTime":"0","endTime":"0","summary":"Research highlights AAV manufacturing optimization via Lexeo’s Sf9-baculovirus process. NEW YORK, May 01, 2025  -- Lexeo Therapeutics, Inc. , a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced today that new data supporting its AAV manufacturing approach will be presented at the28thAnnual Meeting of the American Society of Gene & Cell Therapy taking place May 13-17, 2025 in New Orleans, LA.“The data being presented at ASGCT underscore the strength of our industry-leading capabilities in AAV manufacturing with high yield and high quality,” said José Manuel Otero, Chief Technical Officer of Lexeo Therapeutics. “Scientists at Lexeo have optimized a manufacturing platform that can maintain purity and potency while significantly improving scalability of production and reducing cost. Ultimately this platform will enable Lexeo to deliver more efficiently against key milestones in our clinical-stage gene therapy programs an","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexeo-therapeutics-present-cmc-data-131600872.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BKVL7J92.USD","BK4535","LU1363072403.SGD","LU0971096721.USD","IE00BZ1G4Q59.USD","BK4006","AFG","BK4139","LU0882574139.USD","BK4130","BK4117","BK4539","LU0170899867.USD","IE00B1BXHZ80.USD","CMC","LU0149725797.USD","FA","IE00BHPRN162.USD","LU0267386448.USD","BK4107","LXEO"],"gpt_icon":0},{"id":"2525194858","title":"Chardan Research Adjusts Lexeo Therapeutics Price Target to $22 From $25, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2525194858","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525194858?lang=en_us&edition=fundamental","pubTime":"2025-04-08 22:31","pubTimestamp":1744122682,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics (LXEO) has an average rating of Buy and mean price target of $22, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LXEO"],"gpt_icon":0},{"id":"2525895201","title":"Lexeo Therapeutics Price Target Maintained With a $23.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2525895201","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525895201?lang=en_us&edition=fundamental","pubTime":"2025-04-08 19:43","pubTimestamp":1744112580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXEO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 08, 2025 07:43 ET (11:43 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO"],"gpt_icon":0},{"id":"2525985818","title":"Lexeo Therapeutics Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2525985818","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525985818?lang=en_us&edition=fundamental","pubTime":"2025-04-08 19:00","pubTimestamp":1744110000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXEO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 08, 2025 07:00 ET (11:00 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO"],"gpt_icon":0},{"id":"2525588711","title":"Lexeo Therapeutics Inc : Chardan Capital Markets Cuts Target Price to $22 From $25","url":"https://stock-news.laohu8.com/highlight/detail?id=2525588711","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525588711?lang=en_us&edition=fundamental","pubTime":"2025-04-08 11:48","pubTimestamp":1744084139,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QL1PZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2525010099","title":"Lexeo Therapeutics Says Potential FA Cardiomyopathy Therapy Improves Cardiac Biomarkers","url":"https://stock-news.laohu8.com/highlight/detail?id=2525010099","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525010099?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:36","pubTimestamp":1744029406,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics  said Monday that interim data from two clinical trials showed that its gene therapy candidate LX2006 led to \"clinically significant\" improvements in cardiac biomarkers and functional measures across all dose cohorts for Friedreich ataxia, or FA, cardiomyopathy.The company said its phase 1/2 trial and Weill Cornell Medicine's phase 1a study also showed that the experimental treatment was associated with increased frataxin protein expression in all participants with cardiac biopsies.Chief Development Officer Sandi See Tai said the data show LX2006 exceeds the thresholds aligned with the US Food and Drug Administration to support accelerated approval in a registrational study expected to begin in early 2026.The company said it expects to begin enrollment in Q2 for the registrational study with a potential efficacy readout in 2027.Lexeo shares were up more than 14% in Monday's premarket activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4535","BK4139","LXEO","FA","BK4130"],"gpt_icon":0},{"id":"2525553018","title":"BRIEF-Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data For Lx2006 In Friedreich Ataxia Cardiomyopathy Supporting Advancement To Registrational Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2525553018","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525553018?lang=en_us&edition=fundamental","pubTime":"2025-04-07 18:03","pubTimestamp":1744020194,"startTime":"0","endTime":"0","summary":"BRIEF-Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data For Lx2006 In Friedreich Ataxia Cardiomyopathy Supporting Advancement To Registrational StudyApril 7 (Reuters) - Lexeo Therapeutics I","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QL049:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO","BK4139"],"gpt_icon":0},{"id":"2525274090","title":"Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for Lx2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2525274090","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525274090?lang=en_us&edition=fundamental","pubTime":"2025-04-07 18:01","pubTimestamp":1744020062,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QL049:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LXEO","BK4139"],"gpt_icon":0},{"id":"2525209027","title":"Lexeo Therapeutics Inc: Lx2006 Generally Well Tolerated With No Signs of Complement Activation or Other Immunogenicity to Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2525209027","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525209027?lang=en_us&edition=fundamental","pubTime":"2025-04-07 18:01","pubTimestamp":1744020062,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QL049:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2525090078","title":"Lexeo Therapeutics : Clinically Meaningful Improvements in Majority of Participants Across Cardiac Biomarkers & Functional Measures","url":"https://stock-news.laohu8.com/highlight/detail?id=2525090078","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525090078?lang=en_us&edition=fundamental","pubTime":"2025-04-07 18:01","pubTimestamp":1744020062,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QL049:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2525090073","title":"Lexeo Therapeutics : Participants With Abnormal Left Ventricular Mass Index  at Baseline Achieved 25% Mean Reduction in Lvmi by 12 Months or Sooner","url":"https://stock-news.laohu8.com/highlight/detail?id=2525090073","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525090073?lang=en_us&edition=fundamental","pubTime":"2025-04-07 18:01","pubTimestamp":1744020062,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QL049:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LXEO","BK4139"],"gpt_icon":0},{"id":"2525610018","title":"Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2525610018","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525610018?lang=en_us&edition=fundamental","pubTime":"2025-04-07 18:00","pubTimestamp":1744020000,"startTime":"0","endTime":"0","summary":"Participants with abnormal left ventricular mass index (LVMI) at baseline achieved 25% mean reduction in LVMI by 12 months or sooner Clinically meaningful improvements in majority of participants acro","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/07/3056510/0/en/Lexeo-Therapeutics-Announces-Positive-Interim-Phase-1-2-Data-for-LX2006-in-Friedreich-Ataxia-Cardiomyopathy-Supporting-Advancement-to-Registrational-Study.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FA","BK4130","BK4139","LXEO","BK4535","BK4539"],"gpt_icon":0},{"id":"2522082082","title":"Lexeo Therapeutics Price Target Maintained With a $23.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2522082082","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522082082?lang=en_us&edition=fundamental","pubTime":"2025-03-26 18:55","pubTimestamp":1742986500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXEO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2025 06:55 ET (10:55 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO"],"gpt_icon":0},{"id":"2522882486","title":"Lexeo Therapeutics price target lowered to $18 from $19 at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2522882486","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522882486?lang=en_us&edition=fundamental","pubTime":"2025-03-26 03:36","pubTimestamp":1742931395,"startTime":"0","endTime":"0","summary":"Leerink lowered the firm’s price target on Lexeo Therapeutics (LXEO) to $18 from $19 and keeps an Outperform rating on the shares. The firm notes t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-price-target-lowered-to-18-from-19-at-leerink?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-price-target-lowered-to-18-from-19-at-leerink?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXEO"],"gpt_icon":0},{"id":"2522881862","title":"Lexeo Therapeutics price target lowered to $20 from $24 at RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2522881862","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522881862?lang=en_us&edition=fundamental","pubTime":"2025-03-26 02:39","pubTimestamp":1742927978,"startTime":"0","endTime":"0","summary":"RBC Capital lowered the firm’s price target on Lexeo Therapeutics (LXEO) to $20 from $24 and keeps an Outperform rating on the shares after its Q4 ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-price-target-lowered-to-20-from-24-at-rbc-capital?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-price-target-lowered-to-20-from-24-at-rbc-capital?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXEO"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":54,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LXEO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-12","symbol":"LXEO","fiscalQuarterEnding":"2025/03","expectedEps":-0.8,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"pre","actualEps":-0.99}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LXEO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LXEO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.5714,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":7,"updateTime":1718251200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LXEO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LXEO","date":"2025-06-27","current":-2.06491,"percent":0.754476,"low":-8.903248,"twenty":-6.203846,"median":-4.21373,"eighty":-1.629508,"high":-0.6043,"avg":-4.075759,"sd":2.200572,"marketCap":225709077},"quantilePoints":[{"date":"2023-11-03","current":-4.257819,"twenty":-4.257819,"median":-4.257819,"eighty":-4.257819,"marketCap":271355051},{"date":"2023-11-10","current":-4.199758,"twenty":-4.199758,"median":-4.091377,"eighty":-4.048799,"marketCap":267654754},{"date":"2023-11-17","current":-4.292656,"twenty":-4.257819,"median":-4.118472,"eighty":-4.064282,"marketCap":273575228},{"date":"2023-11-24","current":-4.373941,"twenty":-4.270979,"median":-4.199758,"eighty":-4.070475,"marketCap":278755643},{"date":"2023-12-01","current":-4.923587,"twenty":-4.377038,"median":-4.259754,"eighty":-4.081313,"marketCap":313785113},{"date":"2023-12-08","current":-5.031968,"twenty":-4.945263,"median":-4.26556,"eighty":-4.111505,"marketCap":320692333},{"date":"2023-12-15","current":-4.58828,"twenty":-4.855461,"median":-4.333298,"eighty":-4.161824,"marketCap":306423687},{"date":"2023-12-22","current":-5.849059,"twenty":-5.408075,"median":-4.389424,"eighty":-4.194339,"marketCap":390623587},{"date":"2023-12-29","current":-5.805172,"twenty":-5.505138,"median":-4.537237,"eighty":-4.207282,"marketCap":387692577},{"date":"2024-01-05","current":-5.857039,"twenty":-5.805172,"median":-4.621669,"eighty":-4.218567,"marketCap":391156497},{"date":"2024-01-12","current":-5.896937,"twenty":-5.857039,"median":-4.799136,"eighty":-4.257819,"marketCap":393821051},{"date":"2024-01-19","current":-6.012642,"twenty":-5.955803,"median":-4.957419,"eighty":-4.257819,"marketCap":401548257},{"date":"2024-01-26","current":-6.66298,"twenty":-6.148663,"median":-5.403559,"eighty":-4.260916,"marketCap":444980484},{"date":"2024-02-02","current":-6.706868,"twenty":-6.322251,"median":-5.468033,"eighty":-4.26169,"marketCap":447911493},{"date":"2024-02-09","current":-6.714848,"twenty":-6.590366,"median":-5.777243,"eighty":-4.264786,"marketCap":448444404},{"date":"2024-02-16","current":-6.072489,"twenty":-6.589568,"median":-5.827115,"eighty":-4.287237,"marketCap":405545088},{"date":"2024-02-23","current":-6.343796,"twenty":-6.544084,"median":-5.876988,"eighty":-4.341427,"marketCap":423664054},{"date":"2024-03-01","current":-5.8331,"twenty":-6.543286,"median":-5.916886,"eighty":-4.373941,"marketCap":389557765},{"date":"2024-03-08","current":-5.857039,"twenty":-6.520145,"median":-5.890953,"eighty":-4.383231,"marketCap":391156497},{"date":"2024-03-15","current":-6.292966,"twenty":-6.520145,"median":-5.916886,"eighty":-4.447485,"marketCap":417815207},{"date":"2024-03-22","current":-6.028084,"twenty":-6.505782,"median":-5.977118,"eighty":-4.547445,"marketCap":400228597},{"date":"2024-03-28","current":-6.128418,"twenty":-6.497802,"median":-5.937219,"eighty":-4.601636,"marketCap":406890192},{"date":"2024-04-05","current":-5.265543,"twenty":-6.474661,"median":-5.932845,"eighty":-4.625869,"marketCap":349600479},{"date":"2024-04-12","current":-5.241463,"twenty":-6.410602,"median":-5.90231,"eighty":-4.683238,"marketCap":348001696},{"date":"2024-04-19","current":-4.844139,"twenty":-6.359022,"median":-5.876988,"eighty":-4.791277,"marketCap":321621782},{"date":"2024-04-26","current":-4.88026,"twenty":-6.350977,"median":-5.858281,"eighty":-4.83704,"marketCap":324019956},{"date":"2024-05-03","current":-6.182772,"twenty":-6.32828,"median":-5.876988,"eighty":-4.840714,"marketCap":410498948},{"date":"2024-05-10","current":-6.881509,"twenty":-6.410602,"median":-5.90231,"eighty":-4.84735,"marketCap":477707444},{"date":"2024-05-17","current":-6.653707,"twenty":-6.497802,"median":-5.932845,"eighty":-4.860193,"marketCap":461893680},{"date":"2024-05-24","current":-7.346604,"twenty":-6.546981,"median":-6.018356,"eighty":-4.875444,"marketCap":509993878},{"date":"2024-05-31","current":-7.617118,"twenty":-6.584345,"median":-6.028342,"eighty":-4.885879,"marketCap":528772723},{"date":"2024-06-07","current":-8.28154,"twenty":-6.629029,"median":-6.03658,"eighty":-4.908353,"marketCap":574896200},{"date":"2024-06-14","current":-8.903248,"twenty":-6.66298,"median":-6.072489,"eighty":-4.908353,"marketCap":618054597},{"date":"2024-06-21","current":-7.441521,"twenty":-6.711656,"median":-6.103378,"eighty":-4.917985,"marketCap":516582946},{"date":"2024-06-28","current":-7.05236,"twenty":-6.714848,"median":-6.103378,"eighty":-4.921032,"marketCap":489567767},{"date":"2024-07-05","current":-7.066597,"twenty":-6.782675,"median":-6.120366,"eighty":-4.923587,"marketCap":490556127},{"date":"2024-07-12","current":-8.276794,"twenty":-6.842522,"median":-6.15029,"eighty":-4.991251,"marketCap":574566747},{"date":"2024-07-15","current":-8.352728,"twenty":-6.873712,"median":-6.156275,"eighty":-4.995541,"marketCap":579838001},{"date":"2024-08-02","current":-6.198104,"twenty":-6.865914,"median":-6.161186,"eighty":-4.999831,"marketCap":430266153},{"date":"2024-08-09","current":-5.54792,"twenty":-6.840926,"median":-6.144305,"eighty":-5.014306,"marketCap":385131036},{"date":"2024-08-16","current":-5.180835,"twenty":-6.826318,"median":-6.112265,"eighty":-5.010821,"marketCap":400038148},{"date":"2024-08-23","current":-5.215088,"twenty":-6.797868,"median":-6.103378,"eighty":-5.014306,"marketCap":402683028},{"date":"2024-08-30","current":-4.975314,"twenty":-6.782675,"median":-6.066504,"eighty":-4.996865,"marketCap":384168866},{"date":"2024-09-06","current":-4.881117,"twenty":-6.774695,"median":-6.03259,"eighty":-4.924513,"marketCap":376895445},{"date":"2024-09-13","current":-4.22602,"twenty":-6.738787,"median":-6.028084,"eighty":-4.89684,"marketCap":326312109},{"date":"2024-09-20","current":-4.461512,"twenty":-6.721232,"median":-5.996218,"eighty":-4.873838,"marketCap":344495661},{"date":"2024-09-27","current":-3.814978,"twenty":-6.714848,"median":-5.932845,"eighty":-4.83926,"marketCap":294573545},{"date":"2024-10-04","current":-3.900612,"twenty":-6.71405,"median":-5.90231,"eighty":-4.736975,"marketCap":301185746},{"date":"2024-10-11","current":-3.408218,"twenty":-6.71006,"median":-5.876988,"eighty":-4.623769,"marketCap":263165591},{"date":"2024-10-18","current":-3.89633,"twenty":-6.698313,"median":-5.858281,"eighty":-4.466448,"marketCap":300855136},{"date":"2024-10-25","current":-4.238865,"twenty":-6.663872,"median":-5.849059,"eighty":-4.397847,"marketCap":327303939},{"date":"2024-10-31","current":-3.543091,"twenty":-6.66298,"median":-5.819389,"eighty":-4.373941,"marketCap":273579808},{"date":"2024-11-08","current":-3.378247,"twenty":-6.65417,"median":-5.783228,"eighty":-4.26556,"marketCap":260851321},{"date":"2024-11-15","current":-2.970727,"twenty":-6.653707,"median":-5.678921,"eighty":-4.257819,"marketCap":257253067},{"date":"2024-11-22","current":-2.367417,"twenty":-6.629978,"median":-5.544882,"eighty":-4.208893,"marketCap":205008871},{"date":"2024-11-29","current":-3.142556,"twenty":-6.626181,"median":-5.512207,"eighty":-4.166207,"marketCap":272132743},{"date":"2024-12-06","current":-2.703438,"twenty":-6.607553,"median":-5.450079,"eighty":-4.100138,"marketCap":234106904},{"date":"2024-12-13","current":-2.72253,"twenty":-6.599941,"median":-5.414849,"eighty":-4.066934,"marketCap":235760202},{"date":"2024-12-20","current":-2.306323,"twenty":-6.589568,"median":-5.281597,"eighty":-3.914314,"marketCap":199718319},{"date":"2024-12-27","current":-2.588885,"twenty":-6.578686,"median":-5.241463,"eighty":-3.893837,"marketCap":224187120},{"date":"2025-01-03","current":-2.546883,"twenty":-6.570706,"median":-5.215088,"eighty":-3.826967,"marketCap":220549866},{"date":"2025-01-10","current":-2.604159,"twenty":-6.564766,"median":-5.210806,"eighty":-3.754178,"marketCap":225509758},{"date":"2025-01-17","current":-1.981757,"twenty":-6.550955,"median":-5.17013,"eighty":-3.659982,"marketCap":171612264},{"date":"2025-01-24","current":-2.142882,"twenty":-6.53506,"median":-5.110187,"eighty":-3.528106,"marketCap":185565027},{"date":"2025-01-31","current":-2.005371,"twenty":-6.527327,"median":-5.031968,"eighty":-3.425345,"marketCap":173657111},{"date":"2025-02-07","current":-2.070307,"twenty":-6.515357,"median":-5.011134,"eighty":-3.395373,"marketCap":179280293},{"date":"2025-02-14","current":-1.611936,"twenty":-6.499398,"median":-4.991251,"eighty":-3.192195,"marketCap":139587239},{"date":"2025-02-21","current":-1.539361,"twenty":-6.496206,"median":-4.928215,"eighty":-3.10819,"marketCap":133302506},{"date":"2025-02-28","current":-1.142107,"twenty":-6.453914,"median":-4.914373,"eighty":-2.892068,"marketCap":98901859},{"date":"2025-03-07","current":-1.073351,"twenty":-6.437026,"median":-4.893962,"eighty":-2.779043,"marketCap":92947901},{"date":"2025-03-14","current":-1.134467,"twenty":-6.376035,"median":-4.880688,"eighty":-2.703438,"marketCap":98240308},{"date":"2025-03-21","current":-1.027514,"twenty":-6.356851,"median":-4.852166,"eighty":-2.601104,"marketCap":88978596},{"date":"2025-03-28","current":-1.387527,"twenty":-6.34619,"median":-4.840506,"eighty":-2.545356,"marketCap":136439657},{"date":"2025-04-04","current":-0.891258,"twenty":-6.338037,"median":-4.795483,"eighty":-2.464405,"marketCap":87640072},{"date":"2025-04-11","current":-0.732587,"twenty":-6.311324,"median":-4.74555,"eighty":-2.42393,"marketCap":72037483},{"date":"2025-04-17","current":-0.769723,"twenty":-6.30019,"median":-4.649906,"eighty":-2.355198,"marketCap":75689153},{"date":"2025-04-25","current":-1.238984,"twenty":-6.294572,"median":-4.621669,"eighty":-2.271508,"marketCap":121832978},{"date":"2025-05-02","current":-1.590085,"twenty":-6.292966,"median":-4.546304,"eighty":-2.190247,"marketCap":156357855},{"date":"2025-05-09","current":-1.012793,"twenty":-6.292343,"median":-4.461512,"eighty":-2.110502,"marketCap":99590991},{"date":"2025-05-16","current":-0.81978,"twenty":-6.289736,"median":-4.386933,"eighty":-1.999259,"marketCap":89607702},{"date":"2025-05-23","current":-0.935157,"twenty":-6.278497,"median":-4.373941,"eighty":-1.883139,"marketCap":102219157},{"date":"2025-05-30","current":-0.871396,"twenty":-6.262715,"median":-4.292656,"eighty":-1.737224,"marketCap":95249669},{"date":"2025-06-06","current":-0.992845,"twenty":-6.24372,"median":-4.263625,"eighty":-1.61652,"marketCap":108524884},{"date":"2025-06-13","current":-2.052375,"twenty":-6.232879,"median":-4.257819,"eighty":-1.598825,"marketCap":224338921},{"date":"2025-06-20","current":-2.127645,"twenty":-6.223303,"median":-4.238865,"eighty":-1.614228,"marketCap":232566510},{"date":"2025-06-27","current":-2.06491,"twenty":-6.203846,"median":-4.21373,"eighty":-1.629508,"marketCap":225709077}],"updateTime":1751280280863}}}